Figure 3.

(A) Diagram showing the region of lamina IX where the motoneurons are present. (B) Normal synaptophysin labeling. (C) Loss of synaptophysin immunoreactivity in the placebo group, especially in the neuropil adjacent to motoneurons, evidencing synaptic loss. (D) Evidence of significant synaptic preservation following pregabalin treatment. (E and F) Anti-synaptophysin labeling at the remission phase. Note that there is significant difference between placebo- and pregabalin-treated groups. (G) Quantification of the immunolabeling in the different experimental groups during peak disease. (H) Quantification of the immunolabeling in the different experimental groups during remission phase. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar 50 μm. N = 6 for each experimental group.